More science

The science behind the components of Cardio Fortis

We collected some of the numerouos clinical studies about the components of Cardio Fortis.

The science behind Fruitflow®

Fruitflow® was discovered in 1999 at the Rowett Research Institute by Professor Asim Duttaroy, and since then has been the subject of numerous clinical studies – with ten different human trials to date to support its benefits for cardiovascular health. These studies focused on a variety of different areas, from acute and chronic effects to the safety implications of over-consumption, to fully consider all aspects of safety and effectiveness, and found a 97% effectiveness in test subjects.

For instance, a seven-hour time course study was carried out in 23 cannulated human subjects to determine the efficacy of a supplement drink containing Fruitflow® and both the onset and duration of antiplatelet effects. The results found a significant inhibition of baseline platelet function three hours after consumption, which lasted for 12 hours.¹

This was later followed up by a double-blinded, placebo-controlled crossover study conducted on 90 healthy individuals with normal platelet function to determine the suitability of Fruitflow® as a dietary supplement. Again, significant reductions in ex vivo platelet aggregation were observed three hours after supplementation.² When taken regularly (once a day), the maintenance of normal platelet aggregation is continuous and, unlike stronger medical interventions, the prolonged intake of Fruitflow® does not result in adverse side effects, allergic reactions or an increased risk of bleeding.

Proven efficacy: the 2017 O’Kennedy et al. study is a recent randomized controlled trial compared Fruitflow® and aspirin. A total of 47 healthy subjects took part in a double-blind trial that examined the platelet responses to both Fruitflow® and aspirin. Acute and seven-day treatments with 75mg aspirin were compared with control (with and without concomitant Fruitflow®) over a five-hour time course. Platelet aggregation response agonist, platelet thromboxane A2 release, plasma clotting times and time to form a primary haemostatic clot were all measured as a comparison. The results highlighted that the platelet suppression observed after consuming Fruitflow® is approximately one-third of the suppression following daily aspirin consumption, with no side effects. The reversible action of Fruitflow® means it is less likely to overextend over time to form a clot than aspirin, making it more suitable – and safer – for use in primary prevention.³

The science behind resveratrol

A 2016 study led by scientists at Brazilian university Universidade Estadual de Montes Claros (Unimontes) and USA based Texas Tech University fed mice a high-protein, high-polyunsaturated fat diet and also gave them resveratrol supplements. Researchers found the average total cholesterol levels and body weight of the mice decreased, and their levels of “good” HDL cholesterol increased. Resveratrol seems to influence cholesterol levels by reducing the effect of an enzyme that controls cholesterol production.⁴

France-based universities’: Paris Descartes University, Sorbonne Paris Cité, Paris 75006, France. Paris Descartes Universtiy and Pitié-Salpêtrière-Charles Foix Hospital study focused on the relation between resveratrol and oxidation of ’bad’ LDL cholesterol. They found that as an antioxidant, it also may decrease the oxidation of “bad” LDL cholesterol. LDL oxidation contributes to plaque buildup in artery walls.^5, 6

A new insight into resveratrol as an atheroprotective compound: Canadian Research Center on Aging studied resveratrols capability of inhibition of lipid peroxidation and enhancement of cholesterol efflux. They investigated the relationship between the antioxidant effects of resveratrol and its ability to promote cholesterol efflux. According to the study resveratrol appears to be a natural antioxidant that enhances cholesterol efflux. These properties make it a potential natural antioxidant that could be used to prevent and treat CVD.⁷

The science behind rutin

Author Robert Flaumenhaft, an investigator in the Division of Hemostasis and Thrombosis at Harvard-affiliated Beth Israel Deaconess Medical Center (BIDMC) and associate professor of medicine at Harvard Medical School made studies in 2012 about rutin, and it has been shown to inhibit the formation of blood clots in an animal model of thrombosis. “That finding explained how this compound can be both a potent inhibitor of PDI and a safe food supplement.” – concludes Flaumenhaft. The team went on to test rutin in a mouse model of thrombosis. Because they knew that humans would be taking rutin in pill form, they included studies in which the compound was administered orally and determined that it successfully retained its anti-thrombotic properties when it was metabolized following oral ingestion. “Rutin proved to be the most potently anti-thrombotic compound that we ever tested in this model,” says Flaumenhaft. Of particular note, rutin was shown to inhibit both platelet accumulation and fibrin generation during thrombus formation. “Clots occur in both arteries and in veins,” explains Flaumenhaft. “Clots in arteries are platelet-rich, while those in veins are fibrin-rich. This discovery suggests that a single agent can treat and prevent both types of clots.”⁸